Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Wednesday, June 25, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has received FDA Rare Pediatric Disease Designation for its gene therapy PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy. This designation underscores the therapy's potential to address a critical unmet need in pediatric patients. The company utilizes its proprietary ARCUS platform for developing innovative gene editing solutions.
Price reaction · baseline $4.57 (2025-06-24 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
-7.2%
day 1 · peak
-9.4%
day 3
-8.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA designation highlights the potential of PBGENE-DMD.
  • Focus on treating Duchenne Muscular Dystrophy addresses a significant unmet medical need.
  • Precision BioSciences is advancing gene editing therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jun. 25, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S.

Frequently Asked Questions

What is PBGENE-DMD?

PBGENE-DMD is a gene therapy developed by Precision BioSciences for treating Duchenne Muscular Dystrophy.

What designation did PBGENE-DMD receive?

PBGENE-DMD received the FDA Rare Pediatric Disease Designation.

What is the significance of this designation?

This designation highlights the therapy's potential to address a significant unmet need in pediatric patients.

What platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for developing gene editing therapies.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Duchenne Muscular Dystrophy PBGENE-DMD gene editing FDA designation
Last updated: Jun 25, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →